IDYA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IDEAYA Biosciences Inc (IDYA) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The stock has strong positive catalysts, favorable analyst ratings with increased price targets, and promising clinical trial results that indicate significant growth potential. While the company is not yet profitable, its revenue growth and strong pipeline position it well for future success.
The technical indicators show a bullish trend. The MACD is positive and expanding, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and RSI is neutral at 57.529. The stock is trading near support levels (S1: 30.345) with potential upside toward resistance levels (R1: 36.396).
Positive topline results from the Phase 2/3 OptimUM-02 trial, showing a 58% reduction in disease progression risk and improved progression-free survival for metastatic uveal melanoma patients.
Raised price targets from multiple analysts (Wedbush, Guggenheim, RBC Capital, Truist) with consistent 'Buy' or 'Outperform' ratings.
Plans to submit a New Drug Application in the second half of 2026, with potential approval by late 2026 or early
Strong market anticipation and investor confidence reflected in a 20% share price surge ahead of trial results.
The company remains unprofitable with a net income loss of -$83.27M in Q4
EPS dropped by -36.91% YoY, indicating ongoing financial challenges.
In Q4 2025, IDEAYA's revenue increased by 55.37% YoY to $10.88M, showcasing strong growth. However, the company reported a net income loss of -$83.27M, down -36.10% YoY, and EPS dropped to -0.94. Despite these losses, the gross margin remains at 100%, indicating efficient cost management.
Analysts are highly positive on IDYA, with multiple firms raising price targets: Wedbush to $58, Guggenheim to $54, RBC Capital to $53, and Truist to $65. Analysts cite strong clinical trial results, meaningful derisking signals, and potential peak revenue of $800M+ for darovasertib. All firms maintain 'Buy' or 'Outperform' ratings.
